Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19 Boost As Pharma ROI Hits Heights Not Seen For Seven Years, Finds Deloitte

Executive Summary

Expected return on investment for pharma firms jumped sharply to 7% in 2021, driven largely by COVID-19 R&D but even when the pandemic's impact was stripped out, there was an increase in core R&D productivity compared with 2020, a new report from Deloitte has found. The average cost of developing a drug also declined from 2020 to 2021.

You may also be interested in...



2020 Global Biopharma R&D Productivity And Growth Ranking

The decrease in overall R&D productivity continues – a trend that started in 2018. It would be too easy to attribute this fall in R&D productivity to COVID-19 alone.

Executives On The Move: Allergy Therapeutics, Solid Biosciences and More

Recent executive changes in the industry include C-suite changes at Solid Biosciences and Merck & Co. Meanwhile, new directors were appointed at Allergy Therapeutics and Synairgen.

Mirati Forges Path Forward For Adagrasib In mNSCLC Despite Lukewarm Preliminary Early-Stage Data

The US firm’s adagrasib regimen has failed to differentiate itself from Keytruda plus chemotherapy in two early mNSCLC trials but Mirati is nonetheless forging ahead with pivotal development, albeit with strictly defined populations.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC145690

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel